Search

배경 In a randomized controlled trial, the BNT162b2 mRNA vaccine (tozinameran, Pfizer-BioNTech) showed 95% or greater efficacy against symptomatic and severe COVID-19 disease due to SARS-CoV-2. In a randomized controlled trial, the BNT162b2 mRNA vaccine (tozinameran, Pfizer-BioNTech) showed 95% or greater efficacy against symptomatic and severe COVID-19 disease due to SARS-CoV-2. However, BNT162b2 mRNA vaccine effectiveness against infections of the delta variant declined from 93% in first month to 53% after 4 months after fully vaccination. Although the preventive efficacy of vaccines has been confirmed in clinical trials, it has not been evaluated at the community level. In addition, it is possible that the efficacy of vaccines will be lower against new strains as they spread globally. Herein, we performed a prospective observational study of health care workers to assess the SARS-CoV-2 anti- body response after second dose BNT162b2 mRNA COVID-19 vaccination in a single hospital, South Korea. 방법 In prospective observational study, we analyzed SARS-CoV-2 antibodies response about healthcare work- ers at COVID-19 related departments after each first dose and second dose BNT162b2 mRNA COVID-19 vaccination in a single hospital which is designated to infectious disease, South Korea. The study participants were eligible to healthcare workers of this hospital between 01 March 2021 and 11 October 2021. The participants consisted of doctors, nurses, and technicians of departments of laboratory medi- cine and radiology. Total 1,672 healthcare workers were eligible for the SARS CoV-2 vaccination; 256 participants were enrolled in the study. Of the participants, 253 participants were sampled as baseline antibody test in 9 March 2021, 249 participants were completed the fully vaccination, and they had not a S-IgG at baseline test. Blood samples were collected from the participants at the department of laboratory medicine in Jeju National University Hospital. A 10mL blood sample was collected four times from each participant in three serum-separating tubes; visit 1 (within 1 week before first dose vacci- nation), visit 2 (4 weeks after first dose vaccination), visit 3 (3 months after second dose vaccination), and visit 4 (6 months after second dose vaccination). All participants provided written informed consent. A total of 982 samples were obtained and analyzed in parallel using the Alinity I SARS-CoV-2 IgG II Quant assay (Abbott Ireland Diagnostics Division, Sligo,Ireland). In addition, the SARS-CoV-2 IgG II Quant assay is used to aid in the diagnosis of SARS-CoV-2 infection in conjunction with clinical presentation, the assay can also be used to evaluate the immune status of infected individuals and to monitor antibodyresponses in individuals who have received a COVID-19 vaccine, by quantitatively measuring IgG antibodies against the S receptor-binding domain (RBD) of SARS-CoV-2 (S-IgG). IgG antibody levels < 50 AU/mL were considered nonprotective for this test. 결과 A total of 249 participants were enrolled in this study and 982 blood samples were analyzed. The mean age was 38.1 ± 9.5 years, and the female was 145 (58.2%). Of total participants, 166 (66.7%) subjects had positive nAbs (inhibition rates ≥ 20%) at visit 2, 237 (97.5%) subjects had nAb among 243 subjects at visit 3, and 150 subjects (63.3%) had positive nAb among 237 subjects at visit 4. In analysis of S-IgG, the levels of median quantitative antibody were 1275.1 AU/mL (IQR 755.5-2,119.0) at visit 2, 2,765.9 AU/mL (IQR 1,809.8-4138.4) at visit 3, and 970.1 AU/mL (IQR 606.0-1,495.9) at visit 4, respectively. At visit 1, 246 (98.8%) subjects had positive S-IgG (≥50AU/mL), and all participants had positive antibody levels at visit 3 and 4 after fully vaccinated. The characteristics of patients such as age, body mass index, and comorbidity had no relationship with nAbs or S-IgG at all visits. Considering the change of antibody by time, both nAbs and S-IgG at visit 4 were decreased compared to visit 3. The evidence of SARS-CoV-2 infection was not found among all participants till the end of the study. 결론 BNT162b2 mRNA vaccine was effective to protect in healthy healthcare workers at the COVID-19 related departments. The S-IgG maintained well and nAb was waning in six months after fully vacci- nation, this result showed the need for boost shot vaccination in some healthcare workers in six months after fully vaccination. Herein, we suggest that we need further studies for boost shot vacci- nation in low prevalence countries and various population. [ABSTRACT FROM AUTHOR]